San Leandro, CA – VIVIO, a leading drug outcomes company, announced today that Eric Channer has joined the company as Chief Financial Officer.  

Eric is an experienced CFO in the health insurance and medical benefits industry. Prior to VIVIO, Eric was CFO of AmeriBen, a third-party administrator of medical insurance.  He helped lead that company through significant growth, various ownership structures, and a merger with Elevance Health. Eric began his career in public accounting with KPMG. Throughout his career, he has provided cultural and ethical leadership, business acumen, and an unwavering commitment to core values. Eric is active in his community, volunteering time to various charitable organizations. A licensed CPA, Eric received his bachelor’s and master’s degrees in accounting, graduating Magna Cum Laude, from Brigham Young University’s Marriott School of Business.

“Better health outcomes matter,” said Eric.  “Now, I’m part of a corporate ecosystem that uses this knowledge to ensure every patient receives a better health outcome at an affordable cost.”

“We are delighted to have Eric join our leadership team,” said Pramod John, VIVIO CEO.  “His financial skills and health industry experience will greatly benefit our current and future customers, stakeholders and the specialty drug industry as a whole.”

“I have always been a values and purpose-driven individual. Business has great potential to do good in this world, and VIVIO, a public benefit corporation, is rising to that potential,” said Eric.  “We will not only improve the physical health of our members and their families, but we will leave families, businesses, communities, and the world better than we found them.  This is a cause worth fighting for and I’m excited to be a part of VIVIO.”

*   *   *

About VIVIO: We prioritize health outcomes by fixing the following system problems: identifying expensive drug therapies that don’t work even though they have FDA approval; not knowing if a member is responding adequately to the therapy; doctors not reading the clinical trials themselves; the arbitrary line between pharmacy and medical benefit; and, egregious supply chain waste. VIVIO uses clinical trial, patient, and financial data to drive better health outcomes while eliminating wasted spend.  VIVIO Precision Care™ plugs into an employer’s current carriers and PBMs.  In 2021, VIVIO customers spent 67% less on specialty drugs than the national benchmark.

For more information or a higher res image, contact T.J. Tedesco at [email protected]

Apparently the often-low standards for the FDA aren’t low enough. Now we just move trials to poor countries and use control arms that we wouldn’t approve here. VIVIO team member Bishal Gyawali writes about this in the Lancet. Look at the data yourselves and stop listening to the ‘experts’ who are paid to say ‘yes.’

VIVIO clinical team member, Bishal Gyawali, MD, PhD, is part of the team that develops the WHO Essential Medicines List (EML) identifies priority medicines that are most important to public health. Over time, the EML has included an increasing number of cancer medicines. See the details of their ground breaking work.

VIVIO clinical team member, Daniel Goldstein is referenced in Peter Bach’s scathing commentary in Health Affairs on the waste being driven by vial size games played by Pharma. The original article describes how Merck’s increase of vial size has led to billions of dollars of Keytruda being thrown away.

Visit W3Schools

VIVIO clinical team member, Bishal Gyawali, MD, PhD, on why financial toxicity deserves more attention. “The more lung cancer patients had to pay out of pocket for treatment, the less likely they were to adhere to, or continue, therapy, reported researchers, who also found an indication of resulting less-than-ideal survival odds.”

Bishal Gyawali, MD, PhD, VIVIO clinical team member, interviewed. According to Gyawali, “what’s the point in having a drug that does not reach patients because of unaffordability? Both high cost and low probability of clinical benefit should make us question the value of a drug, not hail it as a game-changer.”

Pramod John, PhD, CEO of VIVIO Health, discusses a recent presentation where he spoke about using real-world data to drive better outcomes and lower costs, as well as weighs the benefits of value-based care.